One day after announcing a sizable acquisition, Denmark-based biotech Genmab (GMAB 4.48%) was doing well on the stock exchange Tuesday. That figure was many times higher than the marginal (0.1%) rise of the S&P 500 (^GSPC 0.41%) at that point. Truist Securities analyst Asthika Goonewardene reiterated his buy recommendation on the stock, with a $46 per-share price target. According to reports, he wrote that Genmab is effectively acquiring Merus's late-stage developmental cancer drug petosemtamab for a very attractive price. A 33% price target hikeEchoing similar sentiments, TD Cowen's Yaron Werber significantly raised his price target on Genmab; it now stands at $32 per share, well up from the preceding $24.